Marpai (MRAI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for August 27, 2025, to elect six directors, ratify the auditor, and approve a charter amendment for preferred stock authorization.
Board recommends voting in favor of all proposals; proxy materials are available online and by mail.
Quorum requires a majority of outstanding shares; each share of common stock has one vote.
Proxies not indicating voting instructions will be voted in favor of all proposals.
Voting matters and shareholder proposals
Proposals include: election of six directors, ratification of UHY LLP as auditor for 2025, and amendment to authorize 2,000,000 shares of blank-check preferred stock.
Board unanimously recommends a vote FOR all proposals.
Stockholder proposals for the 2026 annual meeting must be received by the Secretary by the specified deadline.
Board of directors and corporate governance
Nominees: Damien Lamendola, Yaron Eitan, Sagiv Shiv, Jennifer Calabrese, Robert Pons, and Colleen DiClaudio.
Four directors (Shiv, DiClaudio, Pons, Calabrese) are independent per Nasdaq rules.
Board has audit and compensation committees; no standing nominating committee, but independent directors recommend nominees.
Audit committee met four times in 2024; compensation committee also met four times.
Board and committees oversee risk management, with the audit committee focused on financial risks and the compensation committee on executive compensation risks.
Latest events from Marpai
- Q2 2024 saw a 28% revenue drop, $13M net loss, and a $7.6M impairment charge.MRAI
Q2 20242 Feb 2026 - Q3 2024 losses narrowed as cost cuts offset revenue decline, but liquidity risks remain.MRAI
Q3 202415 Jan 2026 - Losses narrowed in 2024; new PBM products and partnerships target 2025 profitability.MRAI
Q4 202426 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing2 Dec 2025 - Facing ongoing losses and liquidity risks, the company relies on new capital to sustain operations.MRAI
Registration Filing29 Nov 2025 - Q2 2025 saw revenue drop but major cost cuts, with profitability targeted for early 2026.MRAI
Q2 202523 Nov 2025 - Revenue fell 27% to $5.4M; net loss improved, but liquidity and funding risks remain.MRAI
Q1 202519 Nov 2025 - Q3 2025 revenue fell 42%, but cost cuts and new funding drive a turnaround amid liquidity risks.MRAI
Q3 202517 Nov 2025